Lv1
10 积分 2024-11-04 加入
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events
13小时前
待确认
Comparison of Interleukin-22 and Interleukin-10 Soluble Receptor Complexes
1个月前
已完结
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
6个月前
已完结
Epidemiology of Chronic Obstructive Pulmonary Disease
6个月前
已完结
Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity
6个月前
已完结
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date
6个月前
已完结
IL-23 inhibition for chronic inflammatory disease
6个月前
已完结
IL-23 inhibition for chronic inflammatory disease
6个月前
已完结
Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression
6个月前
已关闭
Cytokine/Antibody Fusion Protein Design and Evaluation
7个月前
已完结
皖公网安备34019202002308
